Allied Clinical staff encourages those who suffer from persistent asthma to consider enrolling in this clinical study.
This study will compare the effectiveness of an investigational formulation of Glycopyrronium Inhalation Aerosol delivered via metered dose inhaler (MDI) to placebo and commercially available Spiriva Respimat in patients with persistent asthma. The purpose is to evaluate if these treatments will help control your asthma symptoms better when added to your current asthma medication. The study is expected to last 7 months and once you qualify you will be required to visit the clinic once per month. You will be allowed to continue your current asthma treatment and be given an albuterol rescue inhaler (Ventolin).
Insurance is not required to participate, and the investigational medication or Spiriva Respimat and the albuterol rescue inhaler (Ventolin) will be provided at no charge. In addition, patients will receive medical evaluations, procedures, and diagnostic testing at no charge. Compensation will be provided to those that qualify at $86 for each visit you complete, up to a maximum of $1366 for the entire duration of the study.
In order to qualify for the study, patients must meet the following requirements:
- Be between 12 and 80 years of age
- Have a history of asthma and are regularly using one of the following inhalers:
- Advair (fluticasone and salmeterol)
- Breo (fluticasone and vilanterol)
- Dulera (mometasone and formoterol)
- Symbicort (budesonide and formoterol)
- Not pregnant or breastfeeding
- Not a current smoker, nor have smoked for more than 10 years
- Do not have a pacemaker, uncontrolled glaucoma or liver disease
- Have not had cancer within the past 5 years
- Have not been hospitalized for psychiatric disorder in the past year